Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study

View ORCID ProfileAndrea Giacomelli, View ORCID ProfileGabriele Pagani, Anna Lisa Ridolfo, Letizia Oreni, Federico Conti, Laura Pezzati, Lucia Bradanini, Giacomo Casalini, Cinzia Bassoli, Valentina Morena, Simone Passerini, Giuliano Rizzardini, Chiara Cogliati, Elisa Ceriani, Riccardo Colombo, Stefano Rusconi, Cristina Gervasoni, Dario Cattaneo, Spinello Antinori, Massimo Galli
doi: https://doi.org/10.1101/2020.06.05.20123299
Andrea Giacomelli
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Giacomelli
  • For correspondence: andrea.giacomelli@unimi.it
Gabriele Pagani
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriele Pagani
  • For correspondence: andrea.giacomelli@unimi.it
Anna Lisa Ridolfo
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: andrea.giacomelli@unimi.it
Letizia Oreni
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federico Conti
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Pezzati
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Bradanini
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giacomo Casalini
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cinzia Bassoli
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Morena
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Passerini
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuliano Rizzardini
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
3School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiara Cogliati
4Department of Internal Medicine, ASST Fatebenefratelli-Sacco, Luigi Sacco Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisa Ceriani
4Department of Internal Medicine, ASST Fatebenefratelli-Sacco, Luigi Sacco Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riccardo Colombo
5Department of Anesthesiology and Intensive Care, ASST Fatebenefratelli-Sacco, Luigi Sacco Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Rusconi
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Gervasoni
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dario Cattaneo
6Unit of Clinical Pharmacology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spinello Antinori
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Galli
1Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
2Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

As it has been shown that lopinavir (LPV) and hydroxychloroquine (HCQ) have in vitro activity against coronaviruses, they were used to treat COVID-19 during the first wave of the epidemic in Lombardy, Italy.

The aim of this retrospective intent-to-treat analysis of the hospitalized patients who started off-label treatment with LPV/ritonavir (LPV/r)+HCQ between 21 February and 20 March 2020 was to compare the rate of clinical improvement between those who started the treatment within five days of symptom onset (early treatment, ET) and those who started later (delayed treatment, DT). The association between the timing of treatment and the probability of 30-day mortality was also assessed using uni- and multivariable logistic models.

The study involved 172 patients: 43 (25%) in the ET and 129 (75%) in the DT group. The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray’s test P = 0.213). After adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30-day mortality (adjusted odds ratio [aOR] ET vs DT = 1.45, 95% confidence interval 0.50-4.19). Eight percent of the patients discontinued the treatment because of severe gastrointestinal disorders attributable to LPV/r.

The timing of the start of LPV/r+HCQ treatment does not seem to affect the clinical course of hospitalised patients with COVID-19. Together with the severe adverse events attributable to LPV/r, this raises concerns about the benefit of using this combination to treat COVID-19.

Competing Interest Statement

AG received consultancy fees from Mylan and non-financial educational support from Gilead. SR received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen. MG received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. GR received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. SA received support for research activities from Pfizer and Merck Sharp & Dome. GP, LO, CB, FC, LP, LB, SP, AT, GC, VM, PS, CC, EC, AMB, RC, MC, GG have nothing to declare.

Funding Statement

The study was not funded.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by our Comitato Etico Interaziendale Area 1. Al patients signed a written informed consent for the off-label treatment with lopinavir/ritonavir and hydroxychloroquine. Informed consent was waived in the case of patients undergoing mechanical ventilation upon admission.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

  • Abbreviations:
    CCI
    Charlson Comorbidity Index
    ET
    early treatment group
    DT
    delayed treatment group
    paO2
    partial oxygen pressure
    D-d
    D-dimer
    NA
    not assigned
    CRP
    C-reactive protein
    aOR
    adjusted odds ratio
    Log
    logarithmic.
  • LIST OF ABBREVIATIONS

    COVID-19
    coronavirus induced disease
    SARS-CoV-2
    severe acute respiratory syndrome coronavirus 2
    ET
    early treatment
    DT
    delayed treatment
    HCoV-229E
    Human coronavirus 229E
    TNF-1
    Tumor necrosis factor 1
    IL-6
    interleukin 6
    MERS
    Middle Eastern Respiratory Syndrome Coronavirus
    LPV/r
    lopinavir/ritonavir
    HCQ
    hydroxychloroquine
    SIMIT
    Società Italina di Malattie Infettive e Tropicali
    RT-PCR
    real time polymerase chain reaction
    SpO2
    percutaneous oxygen saturation
    CCI
    Charlson comorbidity index
    FiO2
    fraction of inspired oxygen
    PaO2
    arterial partial pressure of oxygen
    IQR
    inter quartile range
    ICU
    intensive care unit
    ECMO
    Extra corporeal membrane oxygenation
    CRP
    C-reactive protein
    OR
    Odds Ratio
    aOR
    adjusted Odds Ratio
    CI
    Confidence Interval
    AE
    Adverse Events
    PA-IC90
    protein-adjusted 90% inhibitory concentration
    ELF
    epithelial lining fluid
    CSF
    cerebrospinal fluid
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted June 12, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study
    Andrea Giacomelli, Gabriele Pagani, Anna Lisa Ridolfo, Letizia Oreni, Federico Conti, Laura Pezzati, Lucia Bradanini, Giacomo Casalini, Cinzia Bassoli, Valentina Morena, Simone Passerini, Giuliano Rizzardini, Chiara Cogliati, Elisa Ceriani, Riccardo Colombo, Stefano Rusconi, Cristina Gervasoni, Dario Cattaneo, Spinello Antinori, Massimo Galli
    medRxiv 2020.06.05.20123299; doi: https://doi.org/10.1101/2020.06.05.20123299
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study
    Andrea Giacomelli, Gabriele Pagani, Anna Lisa Ridolfo, Letizia Oreni, Federico Conti, Laura Pezzati, Lucia Bradanini, Giacomo Casalini, Cinzia Bassoli, Valentina Morena, Simone Passerini, Giuliano Rizzardini, Chiara Cogliati, Elisa Ceriani, Riccardo Colombo, Stefano Rusconi, Cristina Gervasoni, Dario Cattaneo, Spinello Antinori, Massimo Galli
    medRxiv 2020.06.05.20123299; doi: https://doi.org/10.1101/2020.06.05.20123299

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (174)
    • Allergy and Immunology (421)
    • Anesthesia (97)
    • Cardiovascular Medicine (901)
    • Dentistry and Oral Medicine (170)
    • Dermatology (102)
    • Emergency Medicine (257)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
    • Epidemiology (8789)
    • Forensic Medicine (4)
    • Gastroenterology (405)
    • Genetic and Genomic Medicine (1863)
    • Geriatric Medicine (179)
    • Health Economics (388)
    • Health Informatics (1292)
    • Health Policy (644)
    • Health Systems and Quality Improvement (492)
    • Hematology (207)
    • HIV/AIDS (394)
    • Infectious Diseases (except HIV/AIDS) (10565)
    • Intensive Care and Critical Care Medicine (564)
    • Medical Education (193)
    • Medical Ethics (52)
    • Nephrology (218)
    • Neurology (1756)
    • Nursing (103)
    • Nutrition (266)
    • Obstetrics and Gynecology (343)
    • Occupational and Environmental Health (461)
    • Oncology (965)
    • Ophthalmology (283)
    • Orthopedics (107)
    • Otolaryngology (177)
    • Pain Medicine (118)
    • Palliative Medicine (43)
    • Pathology (264)
    • Pediatrics (557)
    • Pharmacology and Therapeutics (265)
    • Primary Care Research (219)
    • Psychiatry and Clinical Psychology (1845)
    • Public and Global Health (3986)
    • Radiology and Imaging (655)
    • Rehabilitation Medicine and Physical Therapy (344)
    • Respiratory Medicine (535)
    • Rheumatology (215)
    • Sexual and Reproductive Health (178)
    • Sports Medicine (166)
    • Surgery (197)
    • Toxicology (37)
    • Transplantation (106)
    • Urology (80)